An Open-Label, Single-Arm Phase II Study of RAD001 in Patients with Mantle Cell Lymphoma who are Refractory or Intolerant to Velcade (Bortezomib).
Phase of Trial: Phase II
Latest Information Update: 01 May 2014
At a glance
- Drugs Everolimus (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms PILLAR-1
- 02 Aug 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov record.
- 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Mar 2012 Planned end date changed from 1 Mar 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History